Tidal Investments LLC Raises Stock Position in Smith & Nephew SNATS, Inc. $SNN

Tidal Investments LLC lifted its holdings in shares of Smith & Nephew SNATS, Inc. (NYSE:SNN) by 60.2% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 267,513 shares of the medical equipment provider’s stock after acquiring an additional 100,565 shares during the quarter. Tidal Investments LLC’s holdings in Smith & Nephew SNATS were worth $7,707,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently added to or reduced their stakes in the company. Equity Investment Corp increased its holdings in Smith & Nephew SNATS by 3.9% in the 4th quarter. Equity Investment Corp now owns 7,502 shares of the medical equipment provider’s stock valued at $246,000 after purchasing an additional 285 shares in the last quarter. Smartleaf Asset Management LLC lifted its stake in shares of Smith & Nephew SNATS by 13.4% during the fourth quarter. Smartleaf Asset Management LLC now owns 2,820 shares of the medical equipment provider’s stock worth $93,000 after purchasing an additional 334 shares in the last quarter. Cary Street Partners Financial LLC lifted its stake in shares of Smith & Nephew SNATS by 1.8% during the fourth quarter. Cary Street Partners Financial LLC now owns 20,255 shares of the medical equipment provider’s stock worth $665,000 after purchasing an additional 365 shares in the last quarter. Parallel Advisors LLC boosted its position in shares of Smith & Nephew SNATS by 20.0% in the first quarter. Parallel Advisors LLC now owns 2,322 shares of the medical equipment provider’s stock worth $74,000 after buying an additional 387 shares during the period. Finally, Clearstead Trust LLC purchased a new stake in shares of Smith & Nephew SNATS in the second quarter worth about $25,000. 25.64% of the stock is owned by hedge funds and other institutional investors.

Smith & Nephew SNATS Stock Down 0.5%

NYSE:SNN opened at $27.50 on Friday. The firm has a 50-day moving average of $29.94 and a two-hundred day moving average of $31.17. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.14 and a quick ratio of 1.11. Smith & Nephew SNATS, Inc. has a 1-year low of $27.23 and a 1-year high of $38.44.

Smith & Nephew SNATS Dividend Announcement

The firm also recently declared a dividend, which will be paid on Friday, November 6th. Investors of record on Friday, October 2nd will be paid a $0.312 dividend. The ex-dividend date is Friday, October 2nd. This represents a dividend yield of 205.0%.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on SNN shares. JPMorgan Chase & Co. reiterated a “neutral” rating on shares of Smith & Nephew SNATS in a report on Thursday, August 6th. Bank of America cut Smith & Nephew SNATS from a “buy” rating to a “neutral” rating in a report on Tuesday, September 8th. Wall Street Zen raised shares of Smith & Nephew SNATS from a “hold” rating to a “buy” rating in a research report on Sunday. Barclays lowered shares of Smith & Nephew SNATS from an “equal weight” rating to an “underweight” rating in a research note on Wednesday, August 5th. Finally, The Goldman Sachs Group reissued a “buy” rating on shares of Smith & Nephew SNATS in a research report on Monday, May 25th. One investment analyst has rated the stock with a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $31.91.

Smith & Nephew SNATS Company Profile

Smith & Nephew plc is a global medical technology company headquartered in the United Kingdom. Founded in 1856 by Thomas James Smith in Hull, the company initially operated as a pharmacy business before expanding into healthcare products and medical devices.

The company develops and manufactures technologies used in orthopaedic reconstruction, sports medicine, and advanced wound management. Its products include joint replacement systems, trauma and extremities devices, arthroscopic equipment, surgical repair technologies, wound dressings, negative-pressure wound therapy systems, and other products designed to support tissue healing and surgical care.

Smith & Nephew serves hospitals, healthcare professionals, and patients in markets around the world.